Topic Hub

FDA Enforcement

FDA Enforcement — every editorial asset The Inspection Record has published on this topic, in one reading path: the free article, the briefing, the case file, and the record. Each rung goes deeper than the one before it.
1 Free Article
Operations
The 503B Regulatory Cliff: What an Inspector Will Reconstruct After June 29
On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. When the comment window closes on June 29, the remaining legal pathway for bulk GLP-1s seals — and inspectors will work backward through the authorization logic behind every release, EAC determination, and CFU continuation decision in the prior twelve months.
2 Inspection Briefing
No Inspection Briefing published for FDA Enforcement yet.
3 Case Files
No Case File published for FDA Enforcement yet.
4 Inspection Response Record
Generated From Your Assessment
Generate the Inspection Response Record for your FDA Enforcement gaps
Take the Decision Trail Assessment — it identifies your highest-risk gaps and generates the record from there. There's no pre-built FDA Enforcement record to browse; this one is built from your own answers.
5 Workbook / Research
No Workbook or Research Report published for FDA Enforcement yet.